SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
第一单位:
Boehringer Ingelheim RCV GmbH & Co KG, 1120, Vienna, Austria.
作者:
主题词
抗肿瘤药(Antineoplastic Agents);细胞系, 肿瘤(Cell Line, Tumor);细胞存活(Cell Survival);DNA解旋酶类(DNA Helicases);后成说, 遗传(Epigenesis, Genetic);食管肿瘤(Esophageal Neoplasms);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);基因敲低技术(Gene Knockdown Techniques);基因敲除技术(Gene Knockout Techniques);人类(Humans);分子靶向治疗(Molecular Targeted Therapy);核蛋白质类(Nuclear Proteins);RNA, 小分子干扰(RNA, Small Interfering);转录因子(Transcription Factors)
DOI
10.1038/s41598-019-48152-x
PMID
31406271
发布时间
2024-01-04
- 浏览3

Scientific reports
11661页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文